CoChat

Brivaracetam and Levetiracetam Suppress Astroglial L-Glutamate Release through Hemichannel via Inhibition of Synaptic Vesicle Protein

Open access
Fukuyama, Kouji, Okada, Motohiro · 2022 · International Journal of Molecular Sciences

The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.

Abstract

To explore the pathophysiological mechanisms of antiseizure and adverse behavioural/psychiatric effects of brivaracetam and levetiracetam, in the present study, we determined the effects of brivaracetam and levetiracetam on astroglial L-glutamate release induced by artificial high-frequency oscillation (HFO) bursts using ultra-high-performance liquid chromatography. Additionally, the effects of brivaracetam and levetiracetam on protein expressions of connexin43 (Cx43) and synaptic vesicle protein 2A (SV2A) in the plasma membrane of primary cultured rat astrocytes were determined using a capillary immunoblotting system. Acutely artificial fast-ripple HFO (500 Hz) burst stimulation use-dependently increased L-glutamate release through Cx43-containing hemichannels without affecting the expression of Cx43 or SV2A in the plasma membrane, whereas acute physiological ripple HFO (200 Hz) stimulation did not affect astroglial L-glutamate release or expression of Cx43 or SV2A. Contrarily, subchronic ripple HFO and acute pathological fast-ripple HFO (500 Hz) stimulations use-dependently increased L-glutamate release through Cx43-containing hemichannels and Cx43 expression in the plasma membrane. Subchronic fast-ripple HFO-evoked stimulation produced ectopic expression of SV2A in the plasma membrane, but subchronic ripple HFO stimulation did not generate ectopic SV2A. Subchronic administration of brivaracetam and levetiracetam concentration-dependently suppressed fast-ripple HFO-induced astroglial L-glutamate release and expression of Cx43 and SV2A in the plasma membrane. In contrast, subchronic ripple HFO-evoked stimulation induced astroglial L-glutamate release, and Cx43 expression in the plasma membrane was inhibited by subchronic levetiracetam administration, but was not affected by brivaracetam. These results suggest that brivaracetam and levetiracetam inhibit epileptogenic fast-ripple HFO-induced activated astroglial transmission associated with hemichannels. In contrast, the inhibitory effect of therapeutic-relevant concentrations of levetiracetam on physiological ripple HFO-induced astroglial responses probably contributes to the adverse behavioural/psychiatric effects of levetiracetam.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms23094473

Cites

72 of 72 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Effects of acute artificial ripple high-frequency oscillation (HFO) (A) and fast-ripple-HFO evoked stimulations (B) on L-glutamate release from cultured astrocytes (gray and blown columns), and the effects of selective connexin43 (Cx43) inhibitor, TAT-GAP19 (20 μM), on HFOs-evoked astroglial L-glutamate release (blue and green columns). Ordinates indicate the mean ± standard deviation (SD) of extracellular L-glutamate level (μM) (n = 6). Abscissas indicate the numbers of HFO-evoked stimulations sets. * p < 0.05, ** p < 0.01; relative to the HFO-evoked stimulation free (0) and @@ p < 0.01; relative to control (TAT-GAP19 free) by multivariate analysis of variance (MANOVA) with Tukey’s post-hoc test.
Figure 1 Effects of acute artificial ripple high-frequency oscillation (HFO) (A) and fast-ripple-HFO evoked stimulations (B) on L-glutamate release from cultured astrocytes (gray and blown columns), and the effects of selective connexin43 (Cx43) inhibitor, TAT-GAP19 (20 μM), on HFOs-evoked astroglial L-glutamate release (blue and green columns). Ordinates indicate the mean ± standard deviation (SD) of extracellular L-glutamate level (μM) (n = 6). Abscissas indicate the numbers of HFO-evoked stimulations sets. * p < 0.05, ** p < 0.01; relative to the HFO-evoked stimulation free (0) and @@ p < 0.01; relative to control (TAT-GAP19 free) by multivariate analysis of variance (MANOVA) with Tukey’s post-hoc test.CC BY · PubMed Central
Figure 2 Effects of acute artificial ripple-HFO and fast-ripple-HFO evoked stimulations (100 sets) on the expression of Cx43 protein in the astroglial plasma membrane fraction. The right-side panel indicates the pseudo-gel images from the capillary immunoblotting results using anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and anti-connexin43 (Cx43) antibodies for blotting. In the left side panel, ordinate: mean ± SD (n = 6) of the relative protein level of Cx43 (per GAPDH).
Figure 2 Effects of acute artificial ripple-HFO and fast-ripple-HFO evoked stimulations (100 sets) on the expression of Cx43 protein in the astroglial plasma membrane fraction. The right-side panel indicates the pseudo-gel images from the capillary immunoblotting results using anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and anti-connexin43 (Cx43) antibodies for blotting. In the left side panel, ordinate: mean ± SD (n = 6) of the relative protein level of Cx43 (per GAPDH).CC BY · PubMed Central
Figure 3 Concentration-dependent effects of acute administration (for 120 min) of brivaracetam (A) and levetiracetam (B) on astroglial L-glutamate release induced by 100 sets fast-ripple-HFO evoked stimulation. Ordinates indicate the mean ± SD of extracellular L-glutamate level (μM) (n = 6). Abscissas indicate the concentration of brivaracetam (blue columns) or levetiracetam (green columns) (μM). ** p < 0.01; relative to the brivaracetam or levetiracetam free (0) by MANOVA with Tukey’s post-hoc test.
Figure 3 Concentration-dependent effects of acute administration (for 120 min) of brivaracetam (A) and levetiracetam (B) on astroglial L-glutamate release induced by 100 sets fast-ripple-HFO evoked stimulation. Ordinates indicate the mean ± SD of extracellular L-glutamate level (μM) (n = 6). Abscissas indicate the concentration of brivaracetam (blue columns) or levetiracetam (green columns) (μM). ** p < 0.01; relative to the brivaracetam or levetiracetam free (0) by MANOVA with Tukey’s post-hoc test.CC BY · PubMed Central
Figure 4 Effects of subchronic artificial ripple-HFO (green columns) and fast-ripple-HFO evoked (blue columns) stimulations for 1, 3, and 7 days on L-glutamate release from cultured astrocytes (A), and the inhibitory effects of TAT-GAP19 (green and blue columns) on subchronic artificial HFO-evoked astroglial L-glutamate release (B). Ordinates indicate the mean ± SD of extracellular L-glutamate level (μM) (n = 6). Abscissa in panel A indicates the days of HFO-evoked stimulations. In (A), * p < 0.05, ** p < 0.01; relative to the HFO-evoked stimulation free (0) by MANOVA with Tukey’s post-hoc test. In (B), * p < 0.05, ** p < 0.01; relative to ripple-HFO or fast-ripple-HFO evoked stimulation (control: TAT-GAP19 free) by Student’s t-test.
Figure 4 Effects of subchronic artificial ripple-HFO (green columns) and fast-ripple-HFO evoked (blue columns) stimulations for 1, 3, and 7 days on L-glutamate release from cultured astrocytes (A), and the inhibitory effects of TAT-GAP19 (green and blue columns) on subchronic artificial HFO-evoked astroglial L-glutamate release (B). Ordinates indicate the mean ± SD of extracellular L-glutamate level (μM) (n = 6). Abscissa in panel A indicates the days of HFO-evoked stimulations. In (A), * p < 0.05, ** p < 0.01; relative to the HFO-evoked stimulation free (0) by MANOVA with Tukey’s post-hoc test. In (B), * p < 0.05, ** p < 0.01; relative to ripple-HFO or fast-ripple-HFO evoked stimulation (control: TAT-GAP19 free) by Student’s t-test.CC BY · PubMed Central
Figure 5 Concentration-dependent effects of subchronic administration of brivaracetam (0, 3, and 10 μM) (A) and levetiracetam (0, 100, and 300 μM) (B) for 7 days (DIV21-28) on astroglial L-glutamate release induced by subchronic ripple-HFO evoked stimulations (100 set) for 7 days. Ordinates indicate the mean ± SD of extracellular L-glutamate level (μM) (n = 6). ** p < 0.01; relative to the free of ripple-HFO evoked stimulation, and @ p < 0.05 relative to levetiracetam free (0) by MANOVA with Tukey’s post-hoc test.
Figure 5 Concentration-dependent effects of subchronic administration of brivaracetam (0, 3, and 10 μM) (A) and levetiracetam (0, 100, and 300 μM) (B) for 7 days (DIV21-28) on astroglial L-glutamate release induced by subchronic ripple-HFO evoked stimulations (100 set) for 7 days. Ordinates indicate the mean ± SD of extracellular L-glutamate level (μM) (n = 6). ** p < 0.01; relative to the free of ripple-HFO evoked stimulation, and @ p < 0.05 relative to levetiracetam free (0) by MANOVA with Tukey’s post-hoc test.CC BY · PubMed Central
Figure 6 Effects of subchronic artificial ripple-evoked stimulations (100 sets for 7 days) on the expression of Cx43 protein in the astroglial plasma membrane fraction. The right-side panel indicates the pseudo-gel images from the capillary immunoblotting results using anti-GAPDH and anti-Cx43 antibodies for blotting. In the left side panel, ordinate: mean ± SD (n = 6) of the relative protein level of Cx43 (per GAPDH). @@ p < 0.01; relative to control, ** p < 0.01; relative to the ripple-HFO evoked stimulation by one-way ANOVA with Tukey’s post-hoc test.
Figure 6 Effects of subchronic artificial ripple-evoked stimulations (100 sets for 7 days) on the expression of Cx43 protein in the astroglial plasma membrane fraction. The right-side panel indicates the pseudo-gel images from the capillary immunoblotting results using anti-GAPDH and anti-Cx43 antibodies for blotting. In the left side panel, ordinate: mean ± SD (n = 6) of the relative protein level of Cx43 (per GAPDH). @@ p < 0.01; relative to control, ** p < 0.01; relative to the ripple-HFO evoked stimulation by one-way ANOVA with Tukey’s post-hoc test.CC BY · PubMed Central
Figure 7 Concentration-dependent effects of subchronic administration of brivaracetam (0, 3 and 10 μM) (A) and levetiracetam (0, 100, and 300 μM) (B) for 7 days on astroglial L-glutamate release induced by subchronic fast-ripple-HFO evoked stimulations (100 set) for 3 or 7 days. Ordinates indicate the mean ± SD of extracellular L-glutamate level (μM) (n = 6). ** p < 0.01; relative to the free of fast-ripple-HFO evoked stimulation (0 days), and @@ p < 0.01; relative to free of brivaracetam or levetiracetam (control) by MANOVA with Tukey’s post-hoc test.
Figure 7 Concentration-dependent effects of subchronic administration of brivaracetam (0, 3 and 10 μM) (A) and levetiracetam (0, 100, and 300 μM) (B) for 7 days on astroglial L-glutamate release induced by subchronic fast-ripple-HFO evoked stimulations (100 set) for 3 or 7 days. Ordinates indicate the mean ± SD of extracellular L-glutamate level (μM) (n = 6). ** p < 0.01; relative to the free of fast-ripple-HFO evoked stimulation (0 days), and @@ p < 0.01; relative to free of brivaracetam or levetiracetam (control) by MANOVA with Tukey’s post-hoc test.CC BY · PubMed Central
Figure 8 Interaction between subchronic artificial fast-ripple-HFO evoked stimulations (100 sets for 7 days) and therapeutic-relevant concentration of brivaracetam (3 μM) and levetiracetam (100 μM) on the protein expression of Cx43 (A) and synaptic vesicle protein 2A (SV2A) (B) in the astroglial plasma membrane fraction. The right-side panel indicates the pseudo-gel images from the capillary immunoblotting results using anti-GAPDH, anti-Cx43 and anti-SV2A antibodies for blotting. In the left side, ordinate: mean ± SD (n = 6) of the relative protein level of Cx43 and SV2A (per GAPDH). @@ p < 0.01; relative to control, * p < 0.05, ** p < 0.01; relative to the fast-ripple-HFO evoked stimulation (without agent) by one-way ANOVA with Tukey’s post-hoc test.
Figure 8 Interaction between subchronic artificial fast-ripple-HFO evoked stimulations (100 sets for 7 days) and therapeutic-relevant concentration of brivaracetam (3 μM) and levetiracetam (100 μM) on the protein expression of Cx43 (A) and synaptic vesicle protein 2A (SV2A) (B) in the astroglial plasma membrane fraction. The right-side panel indicates the pseudo-gel images from the capillary immunoblotting results using anti-GAPDH, anti-Cx43 and anti-SV2A antibodies for blotting. In the left side, ordinate: mean ± SD (n = 6) of the relative protein level of Cx43 and SV2A (per GAPDH). @@ p < 0.01; relative to control, * p < 0.05, ** p < 0.01; relative to the fast-ripple-HFO evoked stimulation (without agent) by one-way ANOVA with Tukey’s post-hoc test.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 22

Metadata

Authors
Fukuyama, K., & Okada, M.
Affiliations
Mie University (JP)
Corresponding author
Okada, Motohiro
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2022-04-19
Volume
23
Issue
9
Pages
4473
ISSN
1422-0067 (ISSN-L)
OpenAlex
W4280525086
Cited by
22
References
72
Citations by year
2026: 5 · 2025: 5 · 2024: 5 · 2023: 3 · 2022: 4
FWCI
2.77
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Japan Epilepsy Research Foundation (JERF TENKAN 21008)
Topics
  • Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Connexins and lens biology
Keywords
brivaracetam, levetiracetam, connexin 43, hemichannels, SV2A, epileptogenic activity, antiepileptic drugs, astrocytes
MeSH terms
Levetiracetam, Animals, Anticonvulsants, Astrocytes, Pyrrolidinones, Synaptic Vesicles, Connexin 43, Glutamic Acid, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.